[18F]F-AraG PET Imaging in Alzheimer's Disease (NCT07611357) | Clinical Trial Compass
Not Yet RecruitingPhase 2
[18F]F-AraG PET Imaging in Alzheimer's Disease
10 participantsStarted 2026-05-16
Plain-language summary
This study evaluates the use of \[18F\]F-AraG PET/CT imaging to quantify activated T cell involvement in patients with Alzheimer's disease (AD). Participants will undergo total-body dynamic PET imaging to assess tracer uptake in the brain and peripheral organs. Results will be compared between participants with AD and healthy controls to characterize both central nervous system and systemic immune alterations in AD
Who can participate
Age range
55 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Age ≥ 55 years
. Prior volumetric brain MRI available. If the prior MRI scan is not acquired within 6 months of \[18F\]F-AraG imaging or if the investigator determines that prior MRI scan cannot be used, a new MRI scan will be acquired.
. Able to tolerate a PET scan, and willingness and ability to comply with all protocol required procedures.
. For participants of reproductive potential - defined as individuals who have not been post-menopausal for at least 24 consecutive months (i.e., who have had menses within the preceding 24 months), or who have not undergone surgical sterilization, specifically hysterectomy and/or bilateral oophorectomy or bilateral salpingectomy - willingness to use effective double barrier contraceptive methods (excluding withdrawal or timing methods) up to 1 day after the administration of \[18F\]F-AraG
. Subjects with possible or probable AD based on the NIA-Alzheimer's Association working group's diagnostic guidelines for AD.
. Have a study partner who has significant interaction with the subject and can report on the subject's activities of daily living.
Exclusion criteria
. Clinically significant psychiatric disease other than depression.
. Structural brain abnormalities on MRI (e.g. large infarct or mass) likely to interfere with interpretation of a PET scan.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial uses a radioactive PET tracer called [¹⁸F]F-AraG that hasn't been widely studied in Alzheimer's patients yet — since it's a Phase 2 trial, what do we actually know so far about whether this tracer is safe to receive?
2The trial is listed as 'not yet recruiting,' so realistically how long might it be before it opens and I could even be considered for it, and is there anything I should be doing in the meantime?
3From what I understand, this study seems focused on imaging and measuring how the tracer moves through the brain rather than treating Alzheimer's itself — so is there any direct medical benefit to me personally, or would I mainly be contributing to research?
4The trial is measuring how [¹⁸F]F-AraG is taken up and moves through the brain's blood vessels — does that mean I'd need multiple PET scans or blood draws over time, and how would that fit into my current care schedule?
5Given that this is a diagnostic imaging study and not a treatment trial, would it make more sense for me to first focus on standard Alzheimer's care options, and could participating in this study interfere with any of those treatments?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
[¹⁸F]F-AraG uptake in the brain of patients with AD
Timeframe: Imaging visit (~70 minutes)
2
[¹⁸F]F-AraG uptake kinetics in the brain of patients with AD
Timeframe: Imaging visit (~70 minutes)
3
[¹⁸F]F-AraG vascular kinetics in the brain of patients with AD
. History of significant alcohol or substance abuse/dependence within the past 5 years.
. Non-study related radiopharmaceutical imaging or treatment procedure within 7 days prior to the PET imaging session.
. Current or recent investigational drug use, defined as receiving any investigational medications or participation in another investigational drug trial within the last 30 days.
. Serious comorbidities (malignant and nonmalignant disease or other conditions) that in the opinion of the investigator could compromise study objectives.
. Conditions affecting immune function or conditions caused by immune system malfunction that could interfere with imaging, including known inflammatory or immune disorders, systemic malignancy, or chronic viral infections.
. Pregnant or nursing individuals. All participants of reproductive potential will undergo a urine or HCG serum pregnancy test with a sensitivity of at least 25 mIU/mL at screening and on the day of PET/CT imaging.